/ALTHX.PA
ALTHX.PA Stock - THX Pharma
Healthcare|Medical - PharmaceuticalsPAR
$2.00-2.91%
$0.06 (-2.91%) • Dec 23
66
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.77
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.62
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $2.20
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ALTHX.PA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.98 – $2.02
TARGET (TP)$2.30
STOP LOSS$1.84
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.45
52W High$3.66
52W Low$0.26
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.28M | $296,331 | $414,898 | $602 | $294,609 |
| Gross Profit | $-333,550 | $-4,638,690 | $82,898 | $-8,821,970 | $-5,313,454 |
| Gross Margin | -14.6% | -1565.4% | 20.0% | -1465443.5% | -1803.6% |
| Operating Income | $-4,810,269 | $-7,643,677 | $-6,257,000 | $-9,512,810 | $-6,393,630 |
| Net Income | $-1,765,156 | $-6,827,952 | $-6,567,000 | $-8,150,414 | $-4,797,597 |
| Net Margin | -77.3% | -2304.2% | -1582.8% | -1353889.4% | -1628.5% |
| EPS | $-0.21 | $-0.88 | $-1.24 | $-1.66 | $-1.18 |
Company Overview
Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company's lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's disease; and THN101 to treat neuropathic pain. The company was founded in 2013 and is based in Lyon, France.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ALTHX.PABeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.13
Q3 2025
EPS Surprise History
Q4 21
No data
Q2 22
No data
Q4 22
No data
Q2 23
No data
Q2 23
No data
Q2 24
No data
Q4 24
No data
Q3 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Sep 25, 2025 | — | $-0.13 | — | — |
Q2 2025 | Apr 29, 2025 | — | — | — | — |
Q4 2024 | Oct 23, 2024 | — | $0.01 | — | — |
Q2 2024 | Apr 29, 2024 | — | $-0.41 | — | — |
Q2 2023 | Jun 14, 2023 | — | $-0.69 | — | — |
Q2 2023 | Apr 12, 2023 | — | $-0.62 | — | — |
Q4 2022 | Oct 19, 2022 | — | $-0.62 | — | — |
Q2 2022 | Apr 25, 2022 | — | $-0.81 | — | — |
Q4 2021 | Nov 25, 2021 | — | $-0.81 | — | — |
Q2 2021 | Apr 7, 2021 | — | $-0.47 | — | — |
Q3 2020 | Jul 21, 2020 | — | $-0.80 | — | — |
Q2 2020 | Apr 10, 2020 | — | $-0.78 | — | — |
Q3 2019 | Sep 26, 2019 | — | $-0.90 | — | — |
Q2 2019 | Apr 17, 2019 | — | $-1.04 | — | — |
Q3 2018 | Sep 27, 2018 | — | $-0.66 | — | — |
Q2 2018 | Apr 26, 2018 | — | $-0.26 | — | — |
Q4 2017 | Oct 11, 2017 | — | $-0.80 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-0.29 | — | — |
Q1 2016 | Jan 31, 2016 | — | $-0.23 | — | — |
Q2 2015 | Jun 30, 2015 | — | $-0.15 | — | — |
Latest News
Loading news...
Frequently Asked Questions about ALTHX.PA
What is ALTHX.PA's current stock price?
THX Pharma (ALTHX.PA) is currently trading at $2.00 per share. The stock has moved -2.91% today.
What is the analyst price target for ALTHX.PA?
No analyst price targets are currently available for this stock.
What sector is THX Pharma in?
THX Pharma operates in the Healthcare sector, specifically within the Medical - Pharmaceuticals industry. The company is traded on the PAR exchange.
What is ALTHX.PA's market cap?
THX Pharma has a market capitalization of $0.02 billion, making it a small-cap company.
Does ALTHX.PA pay dividends?
No, THX Pharma does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAELIS.PA
Aelis Farma S.A.
$1.10
Mkt Cap: $0.0B
ALBIO.PA
Biosynex S.A.
$0.58
Mkt Cap: $0.0B
ALBLU.PA
Bluelinea S.A.
$0.46
Mkt Cap: $0.0B
ALIKO.PA
Ikonisys S.A.
$1.64
Mkt Cap: $0.0B
ALINS.PA
Intrasense S.A.
$0.24
Mkt Cap: $0.0B
ALNFL.PA
NFL Biosciences S.A.
$1.16
Mkt Cap: $0.0B
ALPRE.PA
Predilife S.A.
$3.30
Mkt Cap: $0.0B
ALVAL.PA
Valbiotis S.A.
$0.69
Mkt Cap: $0.0B
POXEL.PA
Poxel S.A.
$0.24
Mkt Cap: $0.0B
SIGHT.PA
GenSight Biologics S.A.
$0.12
Mkt Cap: $0.0B
Explore stocks similar to ALTHX.PA for comparison